Vasodilator effects of nebivolol in a rat model of hypertension and a rabbit model of congestive heart failure

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 1, 2007, Pages 56-60

  De Groot, Annemieke A ^a   Mathy, Marie Jeanne ^a   Van Zwieten, Pieter A ^a   Peters, Stephan L M ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Congestive heart failure; Endothelial dysfunction; Hypertension; Nebivolol

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; METHACHOLINE; NEBIVOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEMODYNAMICS; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR RING; VASODILATATION; WISTAR KYOTO RAT;

ANIMALS; AORTA, THORACIC; BENZOPYRANS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; HEART FAILURE; HYPERTENSION; MALE; METHACHOLINE CHLORIDE; MUSCARINIC AGONISTS; RABBITS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; VASODILATION; VASODILATOR AGENTS;

EID: 34547676204     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3180587e35     Document Type: Article

References (32)

1. Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589-1596.
2. Panza JA, Quyyumi AA, Brush JE Jr, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
3. Lopez Farre A, Casado S. Heart failure, redox alterations, and endothelial dysfunction. Hypertension. 2001;38:1400-1405.
4. Sharma R, Davidoff MN. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail. 2002;8:165-172.
5. Kerr S, Brosnan MJ, McIntyre M, et al. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension. 1999;33:1353-1358.
6. Lerman LO, Nath KA, Rodriguez-Porcel M, et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001;37:541-546.
7. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl. 2004;1:2-16.
8. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
9. Gao YS, Nagao T, Bond RA, et al. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol. 1991;17:964-969.
10. Mangrella M, Rossi F, Fici F, et al. Pharmacology of nebivolol. Pharmacol Res. 1998;38:419-431.
11. de Groot AA, Mathy MJ, van Zwieten PA, et al. Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J Cardiovasc Pharmacol. 2003;42:232-236.
12. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112:1198-1205.
13. Gosgnach W, Boixel C, Nevo N, et al. Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway. J Cardiovasc Pharmacol. 2001;38:191-199.
14. Rozec B, Quang TT, Noireaud J, et al. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. Br J Pharmacol. 2006;147:699-706.
15. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation. 2000;102:677-684.
16. Georgescu A, Pluteanu F, Flonta ML, et al. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol. 2005;508:159-166.
17. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107:2747-2752.
18. Garban HJ, Buga GM, Ignarro LJ. Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol. 2004;43:638-644.
19. Cominacini L, Fratta Pasini A, Garbin U, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol. 2003;42:1838-1844.
20. de Groot AA, Mathy MJ, van Zwieten PA, et al. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol. 2004;43:148-153.
21. Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795-3801.
22. Troost R, Schwedhelm E, Rojczyk S, et al. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol. 2000;50:377-379.
23. Bril A, Forest MC, Gout B. Ischemia and reperfusion-induced arrhythmias in rabbits with chronic heart failure. Am J Physiol. 1991;261:H301-H307.
24. Panza JA, Garcia CE, Kilcoyne CM, et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995;91:1732-1738.
25. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
26. Rossi M, Taddei S, Fabbri A, et al. Cutaneous vasodilation to acetylcholine in patients with essential hypertension. J Cardiovasc Pharmacol. 1997;29:406-411.
27. Zeiher AM, Drexler H, Saurbier B, et al. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest. 1993;92:652-662.
28. Drexler H, Hayoz D, Munzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol. 1992;69:1596-1601.
29. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
30. Ulker S, McMaster D, McKeown PP, et al. Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovasc Res. 2003;59:488-500.
31. Fratta Pasini A, Garbin U, Nava MC, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23:589-596.
32. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-225.